Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline

Newsroom

FERRING and CDI sign agreement granting Ferring exclusive marketing rights to VSL#3® in Europe and Canada

Saint Prex, Switzerland – 20 March, 2017  – Ferring Pharmaceuticals and CD Investments (CDI) announced today that they have signed an agreement granting Ferring exclusive European marketing rights to CDI’s VSL#3®. This agreement extends Ferring’s existing rights to market the product in the UK, Italy and Canada.

 

Click here to read more

See more Newsroom

Canada

Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 
Canada

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692

Contact